Mutation-Specific Codon Suppression for Aging and Longevity

Mutation-specific Codon Suppression for Aging and Longevity

VITARNA

Gene Therapy

Artan Bio has proposed a novel approach to address genetic and age-related diseases caused by nonsense mutations. These mutations lead to premature protein translation stops, resulting in incomplete and nonfunctional proteins. The solution involves an engineered suppressor system that specifically recognizes these codons and restores normal protein translation.

Owned by

0x452f3…8C80d

Contract:

0x7b66E…5F9C2

Description

Team

Michael Torres

Research Lead

Organisation

Artan Bio, LLC

Experiment Cost

$91,300.00

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

TRL 3

TRL 4

Hypothesis formulated

Basic principles observed

Technology concept formulated

Experimental proof of concept

Technology validated in lab

Rationale

The project has conducted substantial experimental work including in vitro transfection and AAV9 transduction assays demonstrating p53 protein restoration in disease-relevant Calu-6 cells (R196X/R196X mutation), plus a pilot mouse safety/biodistribution study. However, the in vivo work used wild-type mice rather than disease models, and no efficacy has been demonstrated in disease-relevant animal models or advanced organoid systems. The presence of experimental data with dose-response relationships advances beyond TRL 1, but lack of proof-of-concept efficacy in disease models keeps this at TRL 2.

Assessment

Low Confidence

RecommendationPROMOTE

Total Score3.85

Overall Assessment

Score of 3.85/5.0 indicates a solid TRL-2 project with strong therapeutic rationale and emerging drug candidates. Key strengths include clear biological mechanism linking CpG mutations to aging, reproducible in vitro proof-of-concept across multiple experiments and CROs, promising preliminary mouse safety/biodistribution data, and established manufacturing pathway via Lonza. Critical gaps to address include the significant reduction in transgene delivery with ultra-purified AAV preparations (manufacturing optimization needed), lack of functional efficacy readouts beyond protein expression, limited IP documentation, and need for expanded safety studies. The project is appropriately positioned for transition to TRL-3 pending resolution of manufacturing purification issues and demonstration of functional biological activity.

Weighted Score

Price of VITARNA

$0.455

Project Progress

All updates

All categories

Timeline

Activity

Time	Type	$VITARNA	USD	ETH	From

Project Score

Technology Readiness Level

PRE-TRL

TRL 1

TRL 2

TRL 3

TRL 4

Hypothesis formulated

Basic principles observed

Technology concept formulated

Experimental proof of concept

Technology validated in lab

Rationale

Assessment

Low Confidence

RecommendationPROMOTE

Total Score3.85

Overall Assessment

Weighted Score

Therapeutic Relevance

Strong biological rationale linking CpG mutations to aging (Nature Aging 2025). In vitro proof-of-concept demonstrates p53 restoration in Calu-6 cells with R196X mutation via Western blot and qPCR. Multiple vectors show dose-dependent expression. However, functional readouts (apoptosis, cell cycle arrest) are missing, and mechanism validation is limited to single cell line/single protein target despite claims of broad aging applicability.

Therapeutic Optionality

Significant therapeutic optionality identified: platform targets arginine CGA>TGA mutations across multiple age-related proteins (p53, ATM, BRCA, WRN, ERCC6, PTEN, etc.) and diseases beyond aging including cystic fibrosis, autism, neurological conditions, and cancers. AAV9 broad tissue tropism supports multi-indication potential. Alternative pathway of premature aging post-chemotherapy identified as potential first indication.

Intellectual Property

Patent filings mentioned as underway per IPT funding milestones, but no details on patent claims, filing status, or freedom-to-operate analysis provided. Tokenization via VitaDAO (VitaRNA IP-NFT) represents novel IP structure but unclear commercial protection. AAV9 delivery is established platform with crowded IP landscape. Codon suppressor mechanism may face prior art challenges. Early results could strengthen filings but documentation lacks specificity.

Utility Of Candidates

Lead candidate Artan-102 clearly identified with AAV9 packaging complete. Strong in vitro data showing p53 restoration. Critical manufacturing issue identified: ultra-purified vectors show 27-130x reduction in tRNA delivery vs large-scale preparations (Western blot and Ct data), which needs resolution. Lonza partnership established for GMP manufacturing. Two clinical-compatible vectors (VB250610-1157tpv, VB250610-1162rmu) confirmed functional. Clear differentiation between candidates emerging.

Prospects For Safety

Preliminary mouse safety study (n=4/group, 14 days, IV dosing) shows no body weight changes and no significant blood chemistry findings. Artan-102 detected in all major tissues (liver>heart>lung>pancreas>kidney>brain). Test article well-tolerated. However, study is very small, short duration, and single dose. No toxicity endpoints examined. AAV9 platform has FDA-approved precedents supporting safety profile. Cell debris observation with non-purified virus noted but manageable.